ATTR amyloidosis: Genetics and Basic Science
Merrill D. Benson, Indianapolis, IN, USA
Laura Obici, Pavia, Italy
Molecular mechanisms of ATTR amyloidosis
Maria João Saraiva, Porto, Portugal
Driving forces in ATTR amyloidosis
Vittorio Bellotti, London, UK and Pavia, Italy
Genetic signatures associated with hereditary ATTR amyloidosis
Joel Buxbaum, La Jolla, CA, USA
Factors involved in increased susceptibility to TTR amyloidogenesis
Teresa Coelho, Porto, Portugal
14:40 - 15:00Discussion
Mitsuharu Ueda, Kumamoto, Japan
Tomás Ripoll-Vera, Palma de Mallorca, Spain
OP01High resolution cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary val30met ATTR amyloidosis
Matthias Schmidt, Ulm, Germany
OP02Defining the cardiac amyloid proteome and its association with patient clinical characteristics and outcomes
Taxiarchis Kourelis, Rochester, MN, USA
OP03Immunogenetic profile of purified pathological plasma cells of patients with light chain amyloidosis
Isabel Cuenca, Madrid, Spain
OP04From protein-protein interaction to protein co-expression networks: a systems biology-based perspective to investigate amyloidosis diseases
Dario Di Silvestre, Milano, Italy
OP05Targeting deubiquitylating enzymes USP14 and UCHL5 in systemic immunoglobulin light chain (AL) amyloidosis
Mario Nuvolone, Pavia, Italy
OP06Membrane and soluble b-cell maturation antigen (BCMA) in systemic light-chain amyloidosis
Ping Zhou, Boston, MA, USA
15:52 - 16:10Discussion
Wild-type Transthyretin Amyloidosis – An epidemic hiding in plain sight
Pablo García-Pavía, Madrid, Spain
When the bright side of TTR breaks the heart
Maria João Saraiva, Porto, Portugal
Diagnosis and management of wild type TTR amyloidosis
Julian Gillmore, London, UK
Where the Wild-Type Ones Are
Esther González-López, Madrid, Spain
Organ Transplantation in Systemic Amyloidosis
Claudio Rapezzi, Bologna, Italy
Pablo García-Pavía, Madrid, Spain
Heart transplantation in AL amyloidosis
Arnt V. Kristen, Heidelberg, Germany
Heart transplantation in ATTR amyloidosis
Mathew Maurer, NY, USA
Liver transplantation in hereditary ATTR amyloidosis
Julie Heimbach, Rochester, USA
Kidney transplant in AL amyloidosis and monoclonal immunoglobulin deposition disease: who and when?
Nelson Leung, Rochester, MN, USA
18:40 - 19:00Discussion
Experts’ Discussion on ASCT in AL amyloidosis: burning questions
Efstathios Kastritis, Athens, Greece
Vaishali Sanchorawala, Boston, MA, USA
Heather Landau, New York, NY, USA
Hasib Sidiqi, Rochester, MN, USA
Carlos Fernández de Larrea, Barcelona, Spain
Eli Muchtar, Rochester, MN, USA
• Patient selection
• Decreasing transplant-related mortality
• Pretransplant induction
• ASCT in patients with renal function impairment
• Any role for consolidation or maintenance?
• Is it time for CAR-T cell therapy in AL amyloidosis?